India Gas Crisis Threatens US Generic Drug Supply Chain

Energy Squeeze Hits Critical Drug Manufacturing The Indo-Pacific's pharmaceutical manufacturing powerhouse faces an unprecedented energy crisis that could ripple through US generic drug supply chains within months. India produces approximately 40% of the world's generic drugs and 20% of all pharmaceutical exports globally, with the US importing nearly $18 billion worth of Indian pharmaceuticals annually. The crisis centers on natural gas availability, which serves as both a direct feedstock and primary energy source for Active Pharmaceutical Ingredient (API) manufacturing. Our analysis of India's top pharmaceutical companies reveals significant exposure across the supply chain, with several NSE-listed giants showing vulnerabilities that could impact US drug availability. Sun Pharmaceutical Industries (SUNPHARMA), India's largest drugmaker with a market cap of ₹4.17 trillion, faces moderate risk with ₹2,328 crores in revenue at risk from energy disruptions. The company's heavy reliance on gas-intensive processes for complex generics and specialty APIs makes it particularly vulnerable. Despite a strong ROE of 14.07% and ROCE of 20.21%, the company's PE ratio of 34.34 suggests investors may not be fully pricing in energy supply risks. Dr. Reddy's Laboratories (DRREDDY) presents another critical exposure point, with ₹1,313 crores in revenue at risk. The company's US operations, which generate approximately 45% of total revenues, could face supply disruptions if Indian manufacturing facilities cannot secure adequate gas supplies. The moderate risk classification reflects the company's geographic diversification, but its core API manufacturing remains India-centric. Aurobindo Pharma (AUROPHARMA) faces ₹1,297 crores in potential revenue impact, with particular exposure in antiretroviral and oncology APIs. The company's strong presence in the US generic market, especially in complex injectables, makes any production disruption particularly concerning for American hospi...